跳至主要内容
临床试验/ISRCTN16203579
ISRCTN16203579已完成2 期

Effectiveness of BenZalKonium chloride gel as vaginal contraceptive: a randomised controlled trial among Chinese women

Shanghai Institute of Planned Parenthood Research (China)0 个研究点目标入组 200 人开始时间: 2008年5月29日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

  1. 2012 results in https://www.ncbi.nlm.nih.gov/pubmed/23089047 (added 28/01/2019)

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Eligibility requirements included:
  • 1. Sexually active female
  • 2. Aged 20 - 45 years old
  • 3. Presumably fertile based on at least one delivery record
  • 4. At risk for pregnancy and desiring contraception
  • 5. Having regular menstrual cycle (21 - 35 days) and at least three normal menstrual cycles since the last pregnancy, abortion or hormone contraceptive use
  • 6. Be willing to engage in at least four acts of sexual intercourse per month
  • 7. Use the test products as their primary method of contraception
  • 8. Keep a diary of coital activity, product use, and adverse events
  • 9. At low risk for human immunodeficiency virus (HIV) or other sexually transmitted infection, which was defined as having a single sexual partner (for at least six months prior to study initiation)
  • 10. The subject's sexual partner should not be presumably infertile, have a known allergy to BZK or N-9, or have been treated for sexually transmitted diseases (STDs) within six months prior to study entry

排除标准

  • Exclusion criteria included:
  • 1. Diagnosis of any vaginal infection or any symptom of STDs at baseline
  • 2. Known allergy or hypersensitivity to N-9 or BZK
  • 3. Menopause for more than one month
  • 4. Breastfeeding
  • 5. Vaginal bleeding with unknown reasons
  • 6. Recurrent vaginitis or urinary infection
  • 7. Genitourinary system anomaly
  • 8. Hysteroptosis II or severe cystocele
  • 9. Moderate to severe erosion of cervix
  • 10. Malignant reproductive system tumours

研究者

发起方
Shanghai Institute of Planned Parenthood Research (China)

相似试验